Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates

Core Viewpoint - Acadia Pharmaceuticals reported quarterly earnings of $0.16 per share, exceeding the Zacks Consensus Estimate of $0.12 per share, but down from $0.17 per share a year ago, indicating a mixed performance in earnings despite a positive surprise [1][2]. Financial Performance - The company achieved revenues of $283.99 million for the quarter ended December 2025, which fell short of the Zacks Consensus Estimate by 2.94%, compared to $259.6 million in the same quarter last year [2]. - Over the last four quarters, Acadia has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2]. Stock Performance - Acadia shares have declined approximately 7.9% since the beginning of the year, contrasting with the S&P 500's gain of 0.7% [3]. - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $268.17 million, and for the current fiscal year, it is $0.68 on revenues of $1.19 billion [7]. - The trend of earnings estimate revisions for Acadia was mixed prior to the earnings release, which may influence future stock movements [6]. Industry Context - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8].